药物发现和开发的基本原则 1336条(本栏目收费,不能显示细节,电话13136136841)
anti-target activity, 364–365 365
cardiac action potential, 362–363, 363f 363
cardiovascular targets, 367, 367t 367
electrophysiological patch clamp studies,366 366
[3H]-dofetilide displacement, 364–365,364f 364
hERG channel, 362–363 363
in vitro screening systems, 366–367 367
Langendorff preparation, 367–368, 368f 368
myocyte action potential, 363–364, 363f 363
neurohormonal modulation, 367–368 368
QT interval, 363–364, 364f 364
hyperlipidemia, 325–327, 325f–326f 326
ischemic heart disease, 329–330 330
myocardial infarction, 330–331 331
non-surgical rodent models, 332 332
tachycardia-induced AF model., 331 331
tachycardia-induced HF model, 331 331
hypertension. See also Hypertension 0
deoxycorticosterone acetate (DOCA), 323–324, 324f2K1C model, 323, 324f 324
spontaneously hypertensive rat (SHR), 324 324
telemetry-driven animal system, 325 325
homologous animal models, 312 312
infectious disease animal model, 332 332
influenza virus infection, 334 334
murine thigh infection model,332–333, 333f 333
systemic infection, murine model,333–334, 334f 334
transgenic animal models, 44–45,45f–46f 46